Our Treatment Is Different
Pathogens—like cancer—are notoriously able to evade detection. A tumor is simply a growth of invading cells that have managed to hide from or even suppress the immune system. Traditional treatments tend to launch an all-out chemical assault on the disease, rather than coax the body’s immune system into action.
Cutting-Edge
Our peptide mimetics platform supercharges the body’s own immune system to jumpstart its innate ability to fight disease. This non-toxic treatment is a potential game-changer—especially for many diseases that have had few or no effective treatments.
A passion for creating better treatments
Developing new safe treatments using advanced technology
Cost Effective
Every solution should be available to everyone.
Continuous Development
Just because a solution works does not mean development stops.
Ease of Access
Modern technology allows east to use and access treatments.
Little to No training needed
For a treatment to be truly effective it should be easy to use without the need for special training.
Safety
The safety of treatments is always #1 with very little to nil negative side effects.
Better Solutions
Experience the fusion of imagination and expertise with the latest technology to identify new development targets with great therapeutic benefits.
An array of resources
Our comprehensive range of professionals using such technology as AutoDock Vina Docking, 3D-Shape ROCS Screening, AlphaLISA and HTRF Binding Assays.
Peptide Mimetics
- Selectively activate the immune system to safely respond to disease without triggering immunotoxicity
- Mimic carbohydrates and bind to specific receptors on the cell surface to trigger an anti-tumor response
- Naturally revert to amino acid states and leave the body’s systems
Identification of novel
inhibitors of PD-1/PD-L1 interaction
- Immune checkpoint blockade involving inhibition of the PD1/PD-L1 interaction has provided unprecedented clinical benefits in treating a variety of tumors.
- Identification of small-molecule dimerization and sequestration of PD-L1, leading to effective PD1/PD-L1 , giving effective PD1/PD-L1 inhibition.
- Safer small-molecule PD1/PD-L1 inhibition.
- small-molecule inhibitors can assist in overcoming antibody-associated limitations such as low tumor infiltration, adverse immune reactions and high cost.
“Turning Science into Survival: Targeted Therapies for a Cancer-Free Tomorrow.”
CEO, Grenfell Labs
Join 900+ subscribers
Stay in the loop with everything you need to know.